Role of protease and protease inhibitors in cancer pathogenesis and treatment

Ali Eatemadia, Lorestan University of Medical Sciences and Hammed T. Aiyelabegana, Tehran University of Medical Sciences and Babak Negahdaria, Tehran University of Medical Sciences and Mohammad Ali Mazlomia, Tehran University of Medical Sciences and Hadis Daraee, Lorestan University of Medical Sciences and Nasim Daraeeb, Lorestan University of Medical Sciences and Razieh Eatemadie, Tabriz University of Medical Sciences (2016) Role of protease and protease inhibitors in cancer pathogenesis and treatment. Biomedicine & Pharmacotherapy, 86 (2017). pp. 221-231. ISSN 0753-3322

Preview

Text 20.pdf Download (2MB) | Preview

Abstract

Cancer is the second cause of death in 2015, and it has been estimated to surpass heart diseases as the leading cause of death in the next few years. Several mechanisms are involved in cancer pathogenesis. Studies have indicated that proteases are also implicated in tumor growth and progression which is highly dependent on nutrient and oxygen supply. On the other hand, protease inhibitors could be considered as a potent strategy in cancer therapy. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. In this review, we focus on the role of different types of proteases and protease inhibitors in cancer pathogenesis. Keywords: Protease Protease inhibitor cancer

Actions (login required)

View Item